Table 2.

Change over time in clinical biochemistry parameters during the study period

VariablesVisit 1Visit 2Visit 3Visit 4Visit 5
Serum C-terminal FGF23, RU/ml
 Placebo142 (120–221)204 (119–274)175 (116–258)212 (126–253)236 (128–273)
 Sevelamer166 (120–249)200 (122–306)212 (131–299)222 (132–298)238 (142–276)
Serum intact FGF23, pg/ml
 Placebo71 (42–118)104 (56–162)101 (79–135)102 (73–187)112 (74–204)
 Sevelamer72 (53–109)113 (73–168)113 (87–180)110 (77–147)129 (78–159)
Serum phosphorus, mg/dl
 Placebo3.9±0.53.9±0.73.8±0.63.9±0.73.9±0.6
 Sevelamer3.8±0.53.8±0.73.6±0.63.7±0.73.7±0.6
Serum calcium, mg/dl
 Placebo9.3±0.59.3±0.59.2±0.49.3±0.49.3±0.4
 Sevelamer9.4±0.49.4±0.59.4±0.59.3±0.59.3±0.6
Serum intact PTH, pg/ml
 Placebo103 (71–141)93 (62–115)98 (72–134)87 (67–140)96 (67–123)
 Sevelamer91 (58–123)79 (52–141)94 (67–147)87 (52–158)96 (68–126)
Serum creatinine, mg/dl
 Placebo2.6±0.82.6±0.82.6±0.82.6±0.82.6±0.8
 Sevelamer2.6±0.82.6±0.82.6±0.82.6±0.82.6±0.8
GFR MDRD, ml/min per 1.73 m2
 Placebo28±1027±828±927±928±8
 Sevelamer25±826±926±827±826±9
  • Data are quoted as the mean±SD for normally distributed variables and the median (interquartile range) for non-normally distributed variables. FGF23, fibroblast growth factor 23; RU, relative units; PTH, parathyroid hormone; GFR MDRD, GFR calculated with the Modification of Diet in Renal Disease formula.